# Human Genome Sciences Inc. clinical trials: 23 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials with Human Genome Sciences Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Human Genome Sciences Inc.: 23 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/human-genome-sciences-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| December 20, 2013 | NCT02016963 | An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection | Human Genome Sciences Inc. | Phase 2/3 | Completed | Therapeutic Treatment of Inhalation Anthrax | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02016963) |
| April 24, 2012 | NCT01583530 | Study of Belimumab Administered Subcutaneously to Healthy Subjects | Human Genome Sciences Inc. | Phase 1 | Completed | Healthy | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01583530) |
| September 15, 2011 | NCT01434576 | Study to Evaluate the Pharmacodynamics and Safety of HGS1025 in Patients With Ulcerative Colitis | Human Genome Sciences Inc. | Phase 1 | Withdrawn | Ulcerative Colitis | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01434576) |
| November 16, 2009 | NCT01013818 | A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies | Human Genome Sciences Inc. | Phase 1 | Terminated | Lymphoid Malignancies | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01013818) |
| August 12, 2008 | NCT00732940 | Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE) | Human Genome Sciences Inc. | Phase 2 | Terminated | Systemic Lupus Erythematosus | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00732940) |
| July 2, 2008 | NCT00708006 | A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors | Human Genome Sciences Inc. | Phase 1 | Completed | Advanced Solid Tumors | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00708006) |
| April 14, 2008 | NCT00657007 | Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) | Human Genome Sciences Inc. | Phase 1 | Completed | Systemic Lupus Erythematosus | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00657007) |
| April 10, 2008 | NCT00656006 | A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3 | Human Genome Sciences Inc. | Phase 2 | Completed | Chronic Hepatitis C | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00656006) |
| March 20, 2008 | NCT00639678 | A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects | Human Genome Sciences Inc. | Phase 3 | Completed | Healthy | 322 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00639678) |
| December 31, 2007 | NCT00583830 | A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer | Human Genome Sciences Inc. | Phase 2 | Completed | Non Small Cell Lung Cancer | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00583830) |
| December 31, 2007 | NCT00583557 | A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01 | Human Genome Sciences Inc. | Phase 2 | Terminated | Rheumatoid Arthritis | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00583557) |
| January 19, 2007 | NCT00424476 | A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) | Human Genome Sciences Inc. | Phase 3 | Completed | Systemic Lupus Erythematosus | 865 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00424476) |
| December 14, 2006 | NCT00411385 | Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3 | Human Genome Sciences Inc. | Phase 3 | Completed | Chronic Hepatitis C | 933 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00411385) |
| December 12, 2006 | NCT00410384 | A Study of Belimumab in Subjects With Systemic Lupus Erythematosus | Human Genome Sciences Inc. | Phase 3 | Completed | Systemic Lupus Erythematosus | 819 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00410384) |
| November 22, 2006 | NCT00402428 | Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients | Human Genome Sciences Inc. | Phase 3 | Completed | Chronic Hepatitis C | 1,331 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00402428) |
| April 19, 2006 | NCT00315757 | Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma | Human Genome Sciences Inc. | Phase 2 | Completed | Multiple Myeloma | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00315757) |
| June 27, 2005 | NCT00115908 | A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1 | Human Genome Sciences Inc. | Phase 2 | Completed | Hepatitis C, Chronic | 458 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00115908) |
| June 17, 2005 | NCT00114699 | Safety and Efficacy of an Antibody to CCR5 in Individuals With HIV Who Are Not Currently on Antiretroviral Therapy | Human Genome Sciences Inc. | Phase 1 | Completed | HIV Infections | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00114699) |
| November 24, 2004 | NCT00097435 | A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C | Human Genome Sciences Inc. | Phase 2 | Completed | Hepatitis C | 115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00097435) |
| October 27, 2004 | NCT00094848 | Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) | Human Genome Sciences Inc. | Phase 2 | Completed | Lymphoma, Non-Hodgkin | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00094848) |
| September 28, 2004 | NCT00092924 | Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) | Human Genome Sciences Inc. | Phase 2 | Completed | Carcinoma, Non-Small-Cell Lung | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00092924) |
| November 5, 2003 | NCT00071812 | A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA) | Human Genome Sciences Inc. | Phase 2 | Completed | Arthritis, Rheumatoid | 283 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00071812) |
| October 28, 2003 | NCT00071487 | Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE) | Human Genome Sciences Inc. | Phase 2 | Completed | Lupus Erythematosus, Systemic | 449 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00071487) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 6 |
| Phase 2 | 11 |
| Phase 2/3 | 1 |
| Phase 3 | 5 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 19 |
| Terminated | 3 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Lupus Erythematosus, Systemic | 6 |
| Hepatitis C | 5 |
| Hepatitis C, Chronic | 4 |
| Autoimmune Diseases | 4 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Hepatitis | 2 |
| Arthritis, Rheumatoid | 2 |
| Bronchiolitis Obliterans Syndrome | 1 |
| HIV Infections | 1 |
| Lung Neoplasms | 1 |
| Colitis, Ulcerative | 1 |
| Multiple Myeloma | 1 |
| Immune System Diseases | 1 |
| Lymphoma, Non-Hodgkin | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Spine surgery practices in the United States](https://specstream.ai/data/businesses/spine-surgery-practices/united-states)
- [Pan Asian restaurants in the United States](https://specstream.ai/data/businesses/pan-asian-restaurants/united-states)
- [Indian restaurants in the United States](https://specstream.ai/data/businesses/indian-restaurants/united-states)
- [Egyptian restaurants in the United States](https://specstream.ai/data/businesses/egyptian-restaurants/united-states)
- [Beverage suppliers in the United States](https://specstream.ai/data/businesses/beverage-suppliers/united-states)
- [Vending machine suppliers in the United States](https://specstream.ai/data/businesses/vending-machine-suppliers/united-states)
